Evoglip-100

Composition: Sitagliptin 100 mg

Evoglip 100 contains Sitagliptin 100 mg, offering stronger DPP-4 inhibition for patients requiring enhanced glycemic control. It improves insulin response, reduces liver glucose output, and helps maintain stable blood sugar throughout the day. Evoglip 100 is usually given once daily and is well tolerated, with a low risk of low blood sugar.

Uses:

• Type 2 Diabetes management

• Control of fasting and postprandial glucose

• HbA1c reduction

• Can be used with Metformin, Sulfonylureas, or Insulin

Side Effects:

• Nasal congestion

• Headache

• Stomach upset

• Joint or muscle pain

• Rare: pancreatitis or severe allergic reactions

Other Details:

• Low risk of hypoglycemia

• Weight-neutral medication

• Requires dose adjustment in kidney issues